Continuing Review Requirements in Research Studies
Gain insight into the nuances of continuing review requirements for research studies pre-January 21, 2019, post-January 21, 2019, and for FDA regulated research. Explore when continuing review is necessary and exceptions to this process in various research scenarios.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Dial in (Main): (562) 247-8422 Dial in (Alt): (702) 489-0006 Attendee Access Code: 376-069-593 Slides in Handout Tab VAIRRS How-To Series #1: Tracking Studies that do not Require Continuing Review Regulatory Primer on Continuing Review Soundia Duche, MA, MS Director, Education & Training ORPP&E September 23, 2020
Continuing Review Requirements pre-January 21, 2019 Pre-2018 Common Rule: An IRB shall conduct continuing review of research covered by this policy at intervals appropriate to the degree of risk, but not less than once per year (38 CFR 16.109(e)) Common Rule FDA Regulations: An IRB shall conduct continuing review of research covered by these regulations at intervals appropriate to the degree of risk, but not less than once per year (21 CFR 56.109(f)) FDA Regulations 2
3 Continuing Review Requirements on/after January 21, 2019
FDA Regulated Research: CR Required Non-Exempt Research subject to 2018 Rule: CR Required for SOME Research Continuing Review Requirements on/after January 21, 2019 Non-Exempt Research subject to pre-2018 Rule: CR Required 4
Continuing Review Requirements for Research Subject to the 2018 Requirements IRBs shall conduct continuing review of research requiring review by the convened IRB at intervals appropriate to the degree of risk, but not less than once per year, except in the instances described below: Unless an IRB determines otherwise, continuing review of research is not required in the following circumstances: Research eligible for expedited review Research reviewed by the IRB in accordance with the Limited IRB Review provisions (Exempt categories 2(iii); 3(i)(c); 7; and 8) 5
Continuing Review Requirements for Research Subject to the 2018 Requirements (Continued) Research that has progressed to the point that it involves only one or both of the following: Data analysis, inclusive of analysis of identifiable private information or identifiable biospecimens, or Access to follow-up clinical data obtained from procedures that subjects undergo as part of clinical care IRBs must document the rationale for conducting continuing review of research that does not require Continuing Review. 38 CFR 16.109(f)(1) and 38 CFR 16.115(a)(3) 6
Dont Forget about Research under the Sole Oversight of the R&D Committee Research under the sole oversight of the R&D Committee (to include exempt research) requires continuing review by the R&D Committee. The time frame for continuing review by the R&D Committee may not exceed 365 days (VHA Directive 1200.01 paragraph 9d(1)(d)). 7
When Must Continuing Review Occur When continuing review is required, it must occur on or before the date when approval expires. No provision exists for any grace period to extend the conduct of research beyond the expiration date of IRB or R&D Committee approval. VHA Directive 1200.05 paragraph 5g(19) VHA Directive 1200.01 paragraph 9d(1)(d) 8
Lapses in IRB or R&D Committee Approval If Approval Expires: Local research office must promptly notify the investigator Investigator must stop all research activities including, but not limited to Enrollment of new subjects Continuation of research interventions or interactions with currently participating subjects Data analysis Analysis of identifiable data for IRB-approved studies 9
Additional Steps for Lapses in IRB Approval Investigator must immediately submit to the IRB Chair a list of research subjects who could be harmed by stopping study procedures IRB Chair, with appropriate consultation with the Chief of Staff, determines if subjects on the list may continue participating in the research interventions or interactions 10
Lapses in IRB or R&DC Approval Once study approval has expired, re-review and re- approval must occur by the oversight committee before the study can resume. The committee cannot retrospectively grant approval to cover a period of lapsed approval. Lapses in approval are not considered reportable events as they are not suspensions or terminations of committee approval. However, patterns of non-compliance with the requirements of continuing review should be reviewed to determine if such patterns represent serious or continuing non-compliance. 11
Resources ORD s Guidance on Continuing Review for IRBs: https://www.research.va.gov/resources/policies/guidanc e/ContinuingReview.pdf R&D Committee FAQs: https://www.research.va.gov/programs/orppe/policy/faq /VHA-Directive-1200-01-faq.pdf 12
Contact Information Soundia Duche, MS, MS Director, Education and Training Office of Research Protections, Policy, and Education soundia.duche@va.gov 13
